Keywords
Bifidobacterium quadruple viable tablets
Therapeutic effect
Submitted : 2023-08-28
Accepted : 2023-09-12
Published : 2023-09-27
Abstract
Objective: To study the therapeutic efficacy of patients with ulcerative colitis receiving Bifidobacterium quadruple viable tablets. Methods: 49 cases were selected from ulcerative colitis patients who attended the clinic from February 2021 to November 2022, and were randomly grouped into group A for addition of Bifidobacterium quadruple viable tablets treatment, and group B for conventional medication. The efficacy, inflammatory factors, nutritional indexes, and adverse reactions were compared between the groups. Results: The efficacy of UC patients in group A was higher than that in group B (P < 0.05); the inflammatory factors in group A were lower than that in group B (P < 0.05); nutritional indicators in group A were higher than that in group B (P < 0.05); and the adverse reactions of medication in UC patients in group A were lower than that in group B (P < 0.05). Conclusion: The treatment of UC patients with the addition of Bifidobacterium quadruple viable tablets can improve the nutritional status of the organism, inhibit the progression of inflammation, and is safe and efficient in treating ulcerative colitis.
References
Nie P, Tan C, Li H, 2022, Effect of Bifidobacterium Tetragonum Tablets Combined with Mesalazine in the Treatment of Patients with Active Ulcerative Colitis. Zhongguo Niankang Medicine, 34(7): 42–44 + 48.
Zhu D, 2022, Effect of Astragalus Granules Combined with Bifidobacterium bifidum Tetragonum Tablets in the Adjuvant Treatment of Ulcerative Colitis. Zhongguo Niankang Medicine, 34(6): 94–96 + 100.
Hou J, Zhu M, Li Y, 2020, Effect of Bifidobacterium Tetragonum Tablets Combined with Mesalazine in the Treatment of Patients with Ulcerative Colitis. Chinese Contemporary Medicine, 27(11): 59–62.
Hou L, 2020, Application Effect of Bifidobacterium bifidum Tetragonum Tablets in the Treatment of Ulcerative Colitis. Henan Medical Research, 29(27): 5118–5120.
Wang J, Chen X, Zhao S, 2021, Effect of Jianzhong Huayu Tang Combined with Mesalazine and Bifidobacterium bifidum Tetragonum Tablets in the Treatment of Patients with Active Ulcerative Colitis. Zhongguo Niankang Medicine, 33(15): 79–81.
Wang S, Hua W, Cui G, 2021, Efficacy of Bifidobacterium bifidum Tetragonum Tablets in the Adjuvant Treatment of Ulcerative Colitis and Its Effect on Serum Interleukin-17 and Tumor Necrosis Factor-Alpha Levels. Anhui Medicine, 25(5): 1032–1035.
Zhang C, 2020, Study on the Clinical Therapeutic Value of Mesalazine-Bifidobacterium Tetragonum Tablets in Ulcerative Colitis. Chinese Science and Technology Journal Database (Full Text Version) Medicine and Health, 6(11): 58.
Jia X, 2022, Efficacy of Mesalazine with Bifidobacterium bifidum Quadruple Live Bacterial Regimen in Patients with Ulcerative Colitis. Journal of Mathematical Medicine, 35(11): 1638–1641.
Liu Z, Wang Y, 2022, Effect of Quadruple Therapy Combined with Bifidobacterium bifidum Tetragonum Tablets in the Treatment of Peptic Ulcer in the Elderly. Modern Medicine and Health, 38(12): 2093–2095.
Jiang H, 2021, Study on the Efficacy of Bifidobacterium bifidum Tetragonum Tablets in Adjuvant Treatment of Mild to Moderate Ulcerative Colitis. China Modern Drug Application, 15(16): 116–118.